Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients

Sireesha Koppula, Sarah E. Yost, Amy Sussman, Erika R. Bracamonte, Bruce Kaplan

    Research output: Contribution to journalArticlepeer-review

    12 Scopus citations

    Abstract

    Thrombotic microangiopathy (TMA) is a severe complication of kidney transplantation. TMA may occur de novo or as recurrent disease post-transplant. De novo disease is usually associated with immunosuppressive drugs or can be seen as a part of endothelial damage that accompanies antibody-mediated rejection. Treatment for de novo TMA is limited to plasma exchange and change in immunosuppression. We report two cases of de novo TMA post-transplant that were successfully treated by converting to belatacept for maintenance immunosuppression.

    Original languageEnglish (US)
    Pages (from-to)591-597
    Number of pages7
    JournalClinical Transplantation
    Volume27
    Issue number4
    DOIs
    StatePublished - Jul 1 2013

    Keywords

    • Belatacept
    • Renal transplantation
    • Tacrolimus
    • Thrombotic microangiopathy

    ASJC Scopus subject areas

    • Transplantation

    Fingerprint

    Dive into the research topics of 'Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients'. Together they form a unique fingerprint.

    Cite this